Analysts' Actions: AAPL, INTC, GS, BAC, YHOO


Alpha Natural ( ANR) rated new Buy at Sterne Agee ANR was initiated with a Buy rating, Sterne Agee said. $35 price target. Company remains leveraged to growth in the met coal market.

Apple ( AAPL) estimates, target increased at Morgan Stanley. AAPL estimates were raised through 2013. iPhone continues to drive growth. Overweight rating and new $480 price target.

Apple estimates increased at UBS. AAPL estimates raised through 2013. iPhone purchase and carrier launch delays ahead of 4S cause shortfall. Maintain $510 price target and Buy rating.

Arch Coal ( ACI) rated new Neutral at Sterne Agee. $23 price target. Company faces integration challenges.

Bank of America ( BAC) estimates lowered at Sterne Agee. BAC estimates were cut through 2013. Company will take a while to turn its business around. Neutral rating and $7 price target.

Bank of America numbers lowered at UBS. Shares of BAC now seen reaching $7. Estimates also lowered on weaker capital markets and lower reserve releases. Neutral rating.

Chipotle Mexican Grill ( CMG) rated new Neutral at UBS. $345 price target. Solid near term outlook, but appears appropriately valued.

Citrix Systems ( CTXS) upgraded at Needham from Hold to Buy. $85 price target. Spending on data center projects should remain strong.

Coca-Cola ( KO) estimates lowered at Credit Suisse through 2013. Currency changes are cutting into earnings. Outperform rating and $95 price target.

Coca-Cola numbers lowered at UBS. Shares of KO now seen reaching $73. Estimates also lowered on currency and spending impact. Maintain Buy rating.

Cree ( CREE) estimates, target reduced at Sterne Agee. Shares of CREE now seen reaching $52. Estimates also cut, to match the company's new guidance. Buy rating.

Cree estimates, target lowered at UBS. Shares of CREE now seen reaching $29.50. Estimates also lowered as outlook suggest industry is still bottoming. Neutral rating.

EMC ( EMC) estimates upped at Sterne Agee through 2012. Company is gaining market share and realizing higher margins. Buy rating and $30 price target.

Forest Laboratories ( FRX) numbers reduced at Goldman. Shares of FRX now seen reaching $30. Estimates also cut, given the company's negative operating leverage.

Forest Labs estimates, target cut at UBS. Shares of FRX now seen reaching $32. Estimates also lowered on below guidance launches. Neutral rating.

If you liked this article you might like

The 12 Most Ridiculous Kitchen Appliances You Can Buy From Amazon

How to Get Rich Using Warren Buffett's Favorite Stock Market Indicators

Watch: Apple Just Gave a First Look at Its New Campus

PayPal CEO Reveals How Silicon Valley Could Repair Its Broken Culture